NIce characterization of change in TEV's language from specific dates to the more nebulous "in the near future", as that is something that stuck me as well.
I agree Teva's tone and substance changed in their recent PR, but the simplest explanation for that is they got a deficiency letter from the FDA.
Their statements over time are perfectly consistent with the FDA having at one point told them that their application was doing fine and approval was likely/imminent and then subsequently sending them the deficiency letter.
Unlike most on this board I tend to take Teva's statements mostly at face value, and that (together with the Amphastar disclosures) is primarily why I've been out of my modest MNTA position for some weeks now.
News 
Market Data 
Discover 
AI
